Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.
about
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the futureA high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical AssoA 5-year study of systemic reactions using both shared and patient-specific vaccinesEfficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma.A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia).Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.Current developments for improving efficacy of allergy vaccines.Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis.Chinese Guideline on allergen immunotherapy for allergic rhinitis.EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis.Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.The usefulness of the basophil activation test in monitoring specific immunotherapy with house dust mite allergens.
P2860
Q26768511-B43A3573-2B32-42ED-B82B-45A33EE844B2Q34548671-B79FCBE8-F07E-443F-AE24-1E223B2D8501Q35777126-DA569F72-1ABD-4EB5-9780-C85C8B5C41DDQ37221456-2DB54EA5-3B04-4851-AA7B-006C9B3B43BBQ37575153-99898603-54BD-4B50-8F72-458936BDB842Q37652965-88BFF963-CB88-4F48-8E76-F21D55A77E77Q38112352-872E576E-8EEA-4744-8117-21931DFC94F2Q38503330-308A6C6D-77A8-40B8-8D5A-EA6099C1EB4BQ40790855-0AEE9921-1F3E-41B8-B4D2-745526118CFAQ47149942-624EE5D8-5FCB-4F38-A861-1A349D16CA81Q47764778-1E299F14-EC97-4C9A-8528-856AE070938FQ54525833-74819978-B390-4C87-A9DD-1A6FAFB6DB57Q55189726-59732060-68D5-47F8-9161-8A25A9E61467
P2860
Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Subcutaneous allergen immunoth ...... urrent and novel formulations.
@en
type
label
Subcutaneous allergen immunoth ...... urrent and novel formulations.
@en
prefLabel
Subcutaneous allergen immunoth ...... urrent and novel formulations.
@en
P2093
P2860
P356
P1433
P1476
Subcutaneous allergen immunoth ...... urrent and novel formulations.
@en
P2093
Moisés Calderón
Oliver Pfaar
P2860
P304
P356
10.2217/IMT.12.36
P577
2012-06-01T00:00:00Z